A New At-Home Device Just Got FDA Approval to Treat Depression—Here's What You Need to Know

The US Food and Drug Administration (FDA) has approved the first at-home brain stimulation device to treat moderate to severe major depressive disorder (MDD), marking a major shift in mental health treatment. The FL-100 device from Flow Neuroscience delivers low-intensity transcranial direct-current stimulation (tDCS) to the prefrontal cortex—a brain region that shows reduced activity in many people with depression.

How Does This New Depression Treatment Work?

The FL-100 comes as a small headset that pairs with a mobile app for remote clinical guidance. Users wear the device for about 20-30 minutes once daily, delivering gentle electrical stimulation to specific brain areas. The treatment targets the prefrontal cortex, which research shows has diminished activity in people suffering from depression.

In the FDA approval trial, participants who used the active device experienced an average 58% improvement in depression symptoms compared to a control group after 10 weeks of treatment. Most people saw results in as little as three weeks, with 77% showing their depression score improve by at least three points on clinical scales.

Who Can Use This At-Home Depression Device?

The device is approved for people aged 18 and older with moderate to severe major depressive disorder. It can be used either as a standalone treatment or alongside existing therapies like antidepressants. This is particularly significant since about one-third of the estimated 21 million American adults living with depression don't experience adequate relief from antidepressants or stop taking medication due to side effects.

The treatment has already been used by approximately 30,000 people across Europe since its 2019 approval there, with an additional 25,000 users in the UK, Switzerland, and Hong Kong. Side effects were generally mild and short-term, including:

• Skin Irritation: Temporary redness or sensitivity where the device contacts the scalp
• Headaches: Mild discomfort that typically resolves quickly after treatment sessions
• Short-term Effects: Most side effects were brief and didn't interfere with daily activities

When Will This Depression Treatment Be Available?

The FL-100 device is expected to be available to US patients in the second quarter of 2026. It will be prescribed through clinicians, ensuring proper monitoring and guidance throughout treatment. The approval represents what experts see as a watershed moment for depression treatment.

"We're on a mission to make effective, affordable non-drug treatment available to the millions of Americans suffering from depression," said Erin Lee, CEO of Flow Neuroscience. "Flow's FDA approval is a watershed moment for the treatment of depression: The first step in moving from pharmaceutical treatments to tech-based therapies with minimal side effects."

This approval could be particularly game-changing for people who have struggled to find significant symptom relief through traditional medications. The device paves the way for brain stimulation treatments that were previously considered experimental compared to medication and therapy.